Title : CD79B limits response of diffuse large B cell lymphoma to ibrutinib.

Pub. Date : 2016

PMID : 26699656






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Our data collectively indicate that CD79B overexpression leading to activation of AKT/MAPK is a potential mechanism underlying primary ibrutinib resistance in ABC-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib. ibrutinib AKT serine/threonine kinase 1 Homo sapiens
2 Our data collectively indicate that CD79B overexpression leading to activation of AKT/MAPK is a potential mechanism underlying primary ibrutinib resistance in ABC-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib. ibrutinib AKT serine/threonine kinase 1 Homo sapiens